应激性心肌病的研究进展  

Stress-Induced Cardiomyopathy

作　　者：唐琛 史宏志 韩红亚[3] 刘晓丽[3] 赵亦骢 王琛茜 张佳宜 TANG Chen;SHI Hongzhi;HAN Hongya;LIU Xiaoli;ZHAO Yicong;WANG Chenxi;ZHANG Jiayi(Capital Medical University,Beijing 100069,China;Department of General Surgery,The First Medical Center of Chinese PLA General Hospital,Beijing 100853,China;Geriatric Cardiovascular Center,Beijing Anzhen Hospital,Capital Medical University,Beijing 100029,China)

机构地区：[1]首都医科大学,北京100069 [2]解放军总医院第一医学中心普通外科医学部,北京100853 [3]首都医科大学附属北京安贞医院老年心血管病中心,北京100029

出　　处：《心血管病学进展》2024年第7期593-597,共5页Advances in Cardiovascular Diseases

基　　金：国家重点研发计划“主动健康和人口老龄化科技应对”重点专项(2022YFC3602502);北京市高层次公共卫生技术人才建设项目资助(学科骨干-02-01,学科带头人-03-24);首都医科大学“本科生科研创新”项目(XSKY2023322)。

摘　　要：应激性心肌病是以可逆性室壁运动异常为特征的一种心血管综合征,临床表现与急性冠脉综合征相似,但冠状动脉造影显示冠状动脉解剖正常。应激性心肌病的发病机制尚未完全明确,临床诊断不易,标准治疗药物存在争议,因并发症和复发风险导致预后不佳。现总结应激性心肌病的流行病学、发病机制、诊断和治疗方面的最新进展,以期为改善疾病的预后提供思路。Stress-induced cardiomyopathy,a cardiovascular syndrome characterized by reversible abnormal ventricular wall motion,mimics an acute coronary syndrome,but reveals normal coronary angiography.The underlying mechanism of stress-induced cardiomyopathy remains elusive,the diagnosis is often challenging and the pharmacotherapy is controversial.Due to fatal complications and high risk of recurrence,stress-induced cardiomyopathy has a poor prognosis.The article reviews the latest progress in the epidemiology,pathogenesis,diagnosis and treatment of stress-induced cardiomyopathy,in order to provide ideas for improving the prognosis of the disease.

关 键 词：应激性心肌病 儿茶酚胺 嗜铬细胞瘤 Β肾上腺素受体阻滞剂 

分 类 号：R542.2[医药卫生—心血管疾病]